OTTAWA, ON, Oct. 15, 2021 /CNW/ - Auro Pharma Inc., Pharmascience Inc., and Sivem Pharmaceuticals ULC are recalling multiple lots of prescription losartan tablets, in 25 mg, 50 mg and 100 mg strengths, after tests found an azido impurity (5-(4'-((5-(azidomethyl)-2-butyl-4-chloro-1H imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)-1H tetrazole) above the acceptable limit. Long-term exposure to the impurity at levels above what is considered safe could potentially increase the risk of cancer.
Please see the full advisory for more information, including what Canadians should do and Health Canada's work to address the issue of azido impurities found in certain drugs.
Product |
Company |
DIN |
Lot |
Expiry |
AURO-LOSARTAN HCT 50/12.5 mg |
Auro Pharma Inc. |
02423642 |
ACI5021007B |
05 February 2024 |
AURO-LOSARTAN HCT 50/12.5 mg |
Auro Pharma Inc. |
02423642 |
QX5019009-C |
05 December 2022 |
AURO-LOSARTAN HCT 50/12.5 mg |
Auro Pharma Inc. |
02423642 |
QX5019009-B |
05 December 2022 |
AURO-LOSARTAN HCT 50/12.5 mg |
Auro Pharma Inc. |
02423642 |
QX5019010-A |
05 December 2022 |
AURO-LOSARTAN HCT 50/12.5 mg |
Auro Pharma Inc. |
02423642 |
QX5019011-B |
12 December 2022 |
AURO-LOSARTAN HCT 100/12.5 mg |
Auro Pharma Inc. |
02423650 |
ACO1021003A |
16 February 2024 |
AURO-LOSARTAN HCT 100/12.5 mg |
Auro Pharma Inc. |
02423650 |
QY1018013-A |
04 December 2021 |
AURO-LOSARTAN HCT 100/12.5 mg |
Auro Pharma Inc. |
02423650 |
QY1018015-A |
04 December 2021 |
AURO-LOSARTAN HCT 100/12.5 mg |
Auro Pharma Inc. |
02423650 |
QY1018012-A |
04 December 2021 |
AURO-LOSARTAN HCT 100/12.5 mg |
Auro Pharma Inc. |
02423650 |
QY1018010-A |
03 December 2021 |
AURO-LOSARTAN HCT 100/12.5 mg |
Auro Pharma Inc. |
02423650 |
QY1018012-B |
04 December 2021 |
AURO-LOSARTAN HCT 100/12.5 mg |
Auro Pharma Inc. |
02423650 |
QY1018014-A |
04 December 2021 |
AURO-LOSARTAN HCT 100/12.5 mg |
Auro Pharma Inc. |
02423650 |
QY1018011-A |
03 December 2021 |
AURO-LOSARTAN HCT 100/12.5 mg |
Auro Pharma Inc. |
02423650 |
QY1019009-D |
02 December 2022 |
AURO-LOSARTAN HCT 100/12.5 mg |
Auro Pharma Inc. |
02423650 |
QY1019009-A |
02 December 2022 |
AURO-LOSARTAN HCT 100/25 mg |
Auro Pharma Inc. |
02423669 |
QX1019007-A |
24 June 2022 |
AURO-LOSARTAN HCT 100/25 mg |
Auro Pharma Inc. |
02423669 |
ACI1021007A |
05 February 2024 |
AURO-LOSARTAN HCT 100/25 mg |
Auro Pharma Inc. |
02423669 |
QX1019008-A |
24 June 2022 |
AURO-LOSARTAN HCT 100/25 mg |
Auro Pharma Inc. |
02423669 |
QX1019010-B |
05 December 2022 |
AURO-LOSARTAN HCT 100/25 mg |
Auro Pharma Inc. |
02423669 |
QX1019009-B |
05 December 2022 |
AURO-LOSARTAN HCT 100/25 mg |
Auro Pharma Inc. |
02423669 |
QX1019011-A |
12 December 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
QY1019002-A |
May 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
QY1019001-A |
May 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
QY1019003-A |
May 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
QY1019004-A |
May 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
QY1019008-A |
July 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
QY1019007-B |
July 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
QY1019009-C |
December 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
ACO1021003AR |
February 2024 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
ACO1021001B |
February 2024 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
ACO1021002A |
February 2024 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
QY1019005-A |
May 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
QY1019006-A |
July 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
QY1019007-A |
July 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
QY1019009-B |
December 2022 |
LOSARTAN HCT 100/12.5 mg |
Sivem Pharmaceuticals ULC |
02388979 |
ACO1021001A |
February 2024 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
QX1019001-A |
June 2022 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
QX1019002-A |
June 2022 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
QX1019005-A |
June 2022 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
QX1019004-A |
June 2022 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
QX1019003-A |
June 2022 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
QX1019010-A |
December 2022 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
QX1019009-C |
December 2022 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
ACI1021005B |
February 2024 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
ACI1021006A |
February 2024 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
QX1019006-A |
June 2022 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
QX1019009-A |
December 2022 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
ACI1021005A |
February 2024 |
LOSARTAN HCT 100/25 mg |
Sivem Pharmaceuticals ULC |
02388987 |
ACI1021004A |
February 2024 |
LOSARTAN HCT 50/12.5 mg
|
Sivem Pharmaceuticals ULC |
02388960 |
QX5019001-A |
June 2022 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
QX5019002-A |
June 2022 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
QX5019003-A |
June 2022 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
QX5019008-A |
June 2022 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
QX5019007-A |
June 2022 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
QX5019005-A |
June 2022 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
QX5019006-A |
June 2022 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
QX5019004-A |
June 2022 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
QX5019010-B |
December 2022 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
ACI5021007A |
February 2024 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
ACI5021005A |
February 2024 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
ACI5021006A |
February 2024 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
ACI5021004B |
February 2024 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
QX5019009-A |
December 2022 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
QX5019011-A |
December 2022 |
LOSARTAN HCT 50/12.5 mg |
Sivem Pharmaceuticals ULC |
02388960 |
ACI5021004A |
February 2024 |
pms-LOSARTAN 25 mg TABLETS |
Pharmascience Inc. |
02309750 |
629303 |
October 2023 |
pms-LOSARTAN 25 mg TABLETS |
Pharmascience Inc. |
02309750 |
636356 |
July 2024 |
pms-LOSARTAN 50 mg TABLETS |
Pharmascience Inc. |
02309769 |
629302 |
September 2023 |
pms-LOSARTAN 50 mg TABLETS |
Pharmascience Inc. |
02309769 |
636348 |
June 2024 |
pms-LOSARTAN 50 mg TABLETS |
Pharmascience Inc. |
02309769 |
636357 |
June 2024 |
pms-LOSARTAN 100 mg TABLETS |
Pharmascience Inc. |
02309777 |
629306 |
September 2023 |
pms-LOSARTAN 100 mg TABLETS |
Pharmascience Inc. |
02309777 |
629307 |
September 2023 |
pms-LOSARTAN 100 mg TABLETS |
Pharmascience Inc. |
02309777 |
636346 |
July 2024 |
pms-LOSARTAN 100 mg TABLETS |
Pharmascience Inc. |
02309777 |
636358 |
July 2024 |
Également disponible en français
SOURCE Health Canada
Media Inquiries: Health Canada, (613) 957-2983, [email protected]; Public Inquiries: (613) 957-2991, 1-866 225-0709, [email protected]
Share this article